Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Stock buy-back ups AMO (Advanced Medical Optics) earnings forecast:

This article was originally published in Clinica

Executive Summary

Advanced Medical Optics has raised its earnings outlook for 2006 and 2007 to reflect the impact of the $450m planned note offering and $500m share and note repurchase announced last week (see Clinica No 1209 p 14). The Santa Ana, California-based ophthalmic firm now expects to achieve earnings of $2.03-$2.19 per share for 2006, and over $2.60 per share for 2007. Revenue guidance remains unchanged at $1.02-1.04bn for 2006, and $1.1-1.2bn for 2007.

You may also be interested in...



Top 100 Review: The Calm Before The Storm – But Some Medtechs Already Reflect The Ravages Of COVID-19

2019 saw fewer revenues-boosting major acquisitions by top-tier medtechs. Companies that reported after the calendar year-end were the first to see the consequences of the pandemic on their annual figures.

Hikma Adds Sesen’s Vicineum To MENA Brands

Hikma and Sesen Bio have struck a deal that will see Hikma distribute the Vicineum brand in the MENA region.

Netherlands’ Norgine Sets Up OTC Business And Targets Acquisitions

By establishing a dedicated consumer healthcare subsidiary, Norgine is hoping it can grow its $200m-plus Movicol laxative brand and take advantage of M&A opportunities in the OTC market.

Topics

UsernamePublicRestriction

Register

OM013133

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel